We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$135M
Cap. Flow
-$230M
Cap. Flow %
-31.36%
Top 10 Hldgs %
42.15%
Holding
113
New
16
Increased
22
Reduced
29
Closed
27

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$12M
2
NUVL
Nuvalent
NUVL
+$11.4M
3
ALKS icon
Alkermes
ALKS
+$9.33M
4
ARWR icon
Arrowhead Research
ARWR
+$6.71M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.13M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$20.4M
2
ONC
BeOne Medicines Ltd
ONC
+$13.5M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$8.54M
5
APGE icon
Apogee Therapeutics
APGE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 81.54%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
1
Xenon Pharmaceuticals
XENE
$6.6B
$45M 6.15%
1,144,021
+149,794
+15% +$6.04M
FLNA
2
PUT
Filana Therapeutics
FLNA
$51.2M
$42.7M 5.82%
+1,449,300
New +$33.4M
APGE icon
3
Apogee Therapeutics
APGE
$10.1B
$39M 5.32%
664,198
-172,085
-21% -$8.25M
NUVL
4
DELISTED
Nuvalent
NUVL
$34.5M 4.71%
337,500
+137,500
+69% +$11.4M
ACLX
5
DELISTED
Arcellx
ACLX
$33.4M 4.56%
400,000
-60,000
-13% -$4M
ALKS icon
6
Alkermes
ALKS
$8.79B
$28M 3.82%
1,000,000
+350,000
+54% +$9.33M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$37.3B
$25.2M 3.44%
1,400,000
-50,000
-3% -$875K
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$12.8B
$21.2M 2.9%
100,000
-10,000
-9% -$2.56M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$20.4M 2.79%
400,000
-115,000
-22% -$5.93M
NRIX icon
10
Nurix Therapeutics
NRIX
$2.4B
$19.3M 2.64%
860,399
-51,601
-6% -$1.17M
VERA icon
11
Vera Therapeutics
VERA
$2.76B
$19.2M 2.62%
435,000
+60,000
+16% +$2.28M
VRNA
12
DELISTED
Verona Pharma
VRNA
$18.7M 2.55%
650,000
-50,000
-7% -$1.23M
TEVA icon
13
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$18M 2.46%
1,000,000
-150,000
-13% -$2.63M
AUTL
14
Autolus Therapeutics
AUTL
$383M
$16.3M 2.23%
4,500,000
+200,000
+5% +$798K
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$15.4M 2.11%
965,612
-170,090
-15% -$2.08M
INZY
16
DELISTED
Inozyme Pharma
INZY
$14.8M 2.01%
2,822,318
-33,934
-1% -$176K
SYRE icon
17
Spyre Therapeutics
SYRE
$8.7B
$14.7M 2%
498,420
-15,000
-3% -$418K
KURA icon
18
Kura Oncology
KURA
$964M
$13.4M 1.83%
687,785
+37,785
+6% +$766K
ESTA icon
19
Establishment Labs
ESTA
$2.72B
$12.6M 1.72%
290,447
+67,040
+30% +$2.91M
VRDN icon
20
Viridian Therapeutics
VRDN
$1.99B
$11.9M 1.63%
525,000
+375,000
+250% +$6.13M
WVE icon
21
Wave Life Sciences
WVE
$1.12B
$11.5M 1.57%
1,400,000
+1,025,000
+273% +$6.13M
ORKA
22
Oruka Therapeutics
ORKA
$5.59B
$8.57M 1.17%
349,836
+343,796
+5,692% +$12M
RZLT icon
23
Rezolute
RZLT
$444M
$8.24M 1.13%
1,700,000
-150,000
-8% -$689K
MRUS
24
DELISTED
Merus
MRUS
$8.08M 1.1%
161,741
+36,741
+29% +$1.92M
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$7.98M 1.09%
725,106
-250,500
-26% -$2.79M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Affinity Asset Advisors held 113 positions worth $733M, down 16% from $868M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors withdrew a net $230M in Q3 2024, closing 27 positions and reducing 29 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arvinas worth $5.54M.

  • Affinity Asset Advisors's largest Q3 2024 buy was Arvinas: 225,000 shares worth $5.54M.
  • Affinity Asset Advisors added most to Oruka Therapeutics in Q3 2024, an estimated $12M increase.
  • Affinity Asset Advisors's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $13.5M.
  • Affinity Asset Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $20.4M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $733M portfolio in Q3 2024.
  • Affinity Asset Advisors opened 16 new positions and closed 27 in Q3 2024.
  • Affinity Asset Advisors's portfolio value fell 16% quarter-over-quarter to $733M.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.